Un modello di budget impact per la valutazione economica di tocilizumab come prima linea biologica nei pazienti con artrite reumatoide di grado moderato o severo

Capri S, Benucci M, Iannazzo S, Zaniolo O, D’Arpino A. – Italian Journal of Public Health – Year 8, Volume 7, Number 2, Suppl 2, 2010: S44-53

Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy

Eandi M, Pradelli L, Iannazzo S, Chiroli S, Pontoriero G. – Pharmacoeconomics 2010; 28(11): 1041-54

Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis

Benucci M, Iannazzo S, Zaniolo O, Sabadini L. – Clin Exp Rheumatol 2010; 28(5): 722-7

Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy: results from a survey

Pradelli L, Iannazzo S, Zaniolo O, Botrugno P. – Appl Health Econ Health Policy 2010; 8 (2): 119-128

Cost/effectiveness model of dabigatran in the prevention of venous thromboembolism in major orthopedic surgery: adaptation for Italy

Zaniolo O, Wolowacz SE, Pradelli L. – Farmeconomia e percorsi terapeutici 2010; 11(2): 91-101

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept

Sacchi V, Zaniolo O, Olivieri I. – Farmeconomia e percorsi terapeutici 2010; 11(2): 63-76

Tiotropium in COPD: clinical outcomes and economic evidence

Zaniolo O, Sacchi V, Dal Negro RW. – Farmeconomia e percorsi terapeutici 2010; 11(1): 27-41